At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 102 enrolled
Drug / intervention
Warfarin Dose based on pharmacogeneticsgenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Warfarin Dosing: Pharmacogenetic Algorithm Compared to Pharmacist's Dosing
In Brief
A Phase 4 clinical trial evaluating Warfarin Dose based on pharmacogenetics for Atrial Fibrillation and 2 related conditions. Completed, enrolled 102 participants.
Detailed Summary
This is a prospective comparison of clinician dosing and a pharmacogenetic algorithm in diagnosed patients requiring warfarin therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedAug 2007
Primary CompletionNov 2008
TodayJul 2026
First PostedAug 3, 2007
Enrollment StartAug 1, 2006
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.9 years ago
Interventions
Warfarin Dose based on pharmacogeneticsgenetic
Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm